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MaNew insights into the pathophysiology and natural history of patients with aortic stenosis, coupled with advances in
diagnostic imaging and the dramatic evolution of transcatheter aortic valve replacement, are fueling intense interest in
the management of asymptomatic patients with severe aortic stenosis. An intervention that is less invasive than surgery
could conceivably justify pre-emptive transcatheter aortic valve replacement in subsets of patients, rather than waiting
for the emergence of early symptoms to trigger valve intervention. Clinical experience has shown that symptoms can be
challenging to ascertain in many sedentary, deconditioned, and/or elderly patients. Evolving data based on imaging and
biomarker evidence of adverse ventricular remodeling, hypertrophy, inﬂammation, or ﬁbrosis may radically transform
existing clinical decision paradigms. Clinical trials currently enrolling asymptomatic patients have the potential to
change practice patterns and lower the threshold for intervention. (J Am Coll Cardiol Img 2019;-:-–-)
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ABBR EV I A T I ON S
AND ACRONYMS
ACC = American College of
Cardiology
AHA = American Heart
Association
AS = aortic stenosis
AVA = aortic valve area
AVR = aortic valve
replacement
CAD = coronary artery disease
CMR = cardiac magnetic
resonance
EACTS = European Association
for Cardio-Thoracic Surgery
EF = ejection fraction
ESC = European Society of
Cardiology




LGE = late gadolinium
enhancement
LV = left ventricular
SAVR = surgical aortic valve
replacement
STS = Society of Thoracic
Surgeons
TAVR = transcatheter aortic
valve replacement
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2overload and eventually symptoms, the
onset of which herald a fatal course over 2 to
3 years if not corrected with aortic valve
replacement (AVR). To date, there is no
medical therapy available to either retard or
correct these processes.
The foundational principles of managing
patients with AS derive from the seminal
natural history study of a relatively small
cohort of younger patients published by Ross
and Braunwald (4) a half-century ago and
validated subsequently by more recent re-
ports (5). Patients at risk of AS, such as those
with a congenitally bicuspid valve or child-
hood rheumatic fever, experience a long,
latent phase during which progressive valve
obstruction occurs but clinical events,
including sudden cardiac death (estimated
annual riskw1.0%), are infrequent, such that
the mortality risk of intervention (i.e., AVR)
during this asymptomatic period is believed
to exceed that associated with active sur-
veillance. A strategy of expectant but vigilant
management in which intervention is trig-
gered by the development of symptoms or LV
systolic dysfunction has heretofore appeared
safe even for patients with severe or very
severe AS followed up longitudinally with
clinical and echocardiographic monitoring
(6–8). The Class I recommendations for AVRin patients with severe AS from the updated American
Heart Association/American College of Cardiology
(ACC/AHA) and the European Society of Cardiology/
European Association for Cardio-Thoracic Surgery
(ESC/EACTS) clinical practice guidelines (9,10) are
predicated on these fundamental observations.
However, the treatment paradigm has become
more nuanced over time with the recognition that
conservatively managed asymptomatic patients with
severe AS in other observational series have fared less
well (11,12) and that outcomes after AVR have
improved signiﬁcantly over time. Analyses comparing
early surgical AVR (SAVR) (i.e., within 3 months of
recognition of severe AS) with an expectant approach,
including delayed intervention following the emer-
gence of traditional Class I triggers, have suggested a
survival advantage for early SAVR (13,14). A study-
level meta-analysis of 4 such investigations
comprising 2,486 patients reported a pooled unad-
justed all-cause mortality risk ratio of 0.29 (95%
conﬁdence interval: 0.17 to 0.51) for early SAVR
compared with a conservative strategy (15). It is fair toask whether waiting for symptoms to occur or LV
function to decline may endanger patients in
ways not previously appreciated. This challenge is
especially poignant if patients cannot be followed up
closely and at frequent intervals. Identiﬁcation of
asymptomatic AS patients at higher risk for death or
the imminent need for AVR during follow-up has
been the subject of intense investigation and has led
to several Class II guideline recommendations by
which pre-emptive AVR is believed reasonable or
could be considered in patients at low surgical risk
(9,10). Important risk features include hemodynamic
and echocardiographic responses to exercise, AS
severity by jet velocity, rate of AS progression, pul-
monary hypertension not explained by another
cause, and markedly elevated brain natriuretic pep-
tide levels. There is also widespread interest in the
potential for indices of global longitudinal strain
(GLS) and cardiac magnetic resonance (CMR)-
detected myocardial ﬁbrosis to aid in AS risk stratiﬁ-
cation (16,17) (Central Illustration). Application of
several Class II recommendations for AVR in asymp-
tomatic AS patients has become more commonplace
in practice. A more in-depth discussion of the evalu-
ation and use of early risk features to inform man-
agement of the asymptomatic AS patient is the
subject of the current review.
It is recognized that the renaissance engendered by
the development and explosive growth of trans-
catheter AVR (TAVR) over the past decade, enabled
by the iterative improvements in devices, catheters,
multimodality imaging, patient selection and out-
comes, has fueled increasing interest in revisiting
traditional treatment paradigms for patients with
severe AS. Indeed, a level of clinical equipoise
regarding the management of patients with severe
asymptomatic AS has been reached that would not
previously have been anticipated and now ﬁnds itself
expressed in strategy trials comparing immediate
AVR versus clinical surveillance with deferred AVR
when symptoms develop. Some of these trials are
more broadly inclusive, most notably the randomized
trial of Edwards Sapien 3 TAVR versus active sur-
veillance in the EARLY TAVR (Evaluation of Trans-
catheter Aortic Valve Replacement Compared to
Surveillance for Patients With Asymptomatic Severe
Aortic Stenosis; NCT03042104) trial. The trial proto-
col mandates the use of exercise testing in most pa-
tients, performance on which must be considered
normal before randomization. Other strategy trials
enrolling patients with severe asymptomatic AS
will restrict enrollment to patients with high-risk

























RCTs of early AVR versus clinical surveillance and delayed AVR:
• EARLY TAVR: broad inclusion, severe AS age >65 years
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Evaluation and treatment of patients with asymptomatic severe aortic stenosis (AS). Beyond determination of left ventricular ejection fraction (EF) and
veriﬁcation of asymptomatic status with exercise testing, there are several established indices of disease severity supported by the American Heart
Association/American College of Cardiology (AHA/ACC) and European Society of Cardiology/European Association for Cardio-Thoracic Surgery
(ESC/EACTS) guidelines as well as evolving novel indices. These are now being testing in randomized controlled trials (RCTs) to determine if early aortic
valve replacement (AVR) results in better outcomes than traditional clinical surveillance until onset of symptoms. BNP ¼ brain natriuretic peptide;
EARLY TAVR ¼ Evaluation of Transcatheter Aortic Valve Replacement Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis;
EVOLVED ¼ The Early Valve Replacement Guided by Biomarkers of LV Decompensation in Asymptomatic Patients With Severe AS; HT ¼ hypertension;
LVH ¼ left ventricular hypertrophy. *AVR is recommended using these criteria only if asymptomatic patients are considered low-risk candidates for
surgical AVR.
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3features, such as EVOLVED (Early Valve Replace-
ment Guided by Biomarkers of LV Decompensation
in Asymptomatic Patients With Severe AS;
NCT03094143) trial, which will enroll asymptomatic
patients with evidence of myocardial ﬁbrosis. These
randomized strategy trials and ongoing and future
research on particular high-risk features are antici-
pated to have a signiﬁcant inﬂuence on the
clinical management of patients with severe
asymptomatic AS.THE CASE FOR ECHOCARDIOGRAPHY AND
EXERCISE TESTING
DISEASE SEVERITY AND PROGRESSION.
Echocardiography remains a widely used imaging
modality for initial and serial assessment of asymp-
tomatic patients with AS (Figure 1). Numerous studies
indicate that several echocardiographic criteria,
including stenosis severity, degree of calciﬁcation,
and disease progression, are associated with clinical
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4outcomes (18). Peak aortic jet velocity (Vmax) is a
robust prognostic parameter in AS, with increasing
event rates as patients progress from mild (<3 m/s) to
moderate (3 to 4 m/s), severe (>4 m/s), and very se-
vere (>5 m/s) stenosis (6,8,19). Although the majority
of “events” in previous studies have been the devel-
opment of symptoms warranting AVR, the recent
HAVEC (Heart Valve Clinic International Database)
registry, reporting the natural history in 1,375
asymptomatic patients with AS (20), conﬁrmed that
very severe AS (peak velocity >5 m/s) is predictive of
all-cause mortality during the natural history of AS
without AVR (4-year survival: 83  6% vs. 20  17% in
those with peak velocities <5 m/s vs. >5 m/s,
respectively; p < 0.05) and also in those who undergo
AVR (4-year post-operative survival: 78  4% vs. 65 
10%; p < 0.05). Although current guidelines recom-
mend consideration of AVR in patients with
Vmax >5 to 5.5 m/s if the estimated surgical risk is low
(Class IIa, Level of Evidence: C) (9,10), these hard
endpoints from the HAVEC registry may justify
consideration of a stronger recommendation.
Patients with rapid progression of AS severity
(peak jet velocity increase >0.3 m/s/year) and mod-
erate or severe valve calciﬁcation have a rate of
symptom development or mortality of 79% at 2 years
(7). Although this observation derived from a single
limited observational study (and despite the high
variability in the serial measurement of peak velocity
in practice), it is classiﬁed as a Class IIa recommen-
dation for AVR (9,10).
An increase in global (valvular and vascular) after-
load, as assessed by the valvulo-arterial impedance
(>5 mm Hg/ml/m2) is also a marker of poor clinical
outcome and poor hemodynamic capacity, although
data are limited in asymptomatic patients (18,21).
LV FUNCTION, REMODELING, AND STRAIN. The
chronic increase in global afterload inevitably leads to
cardiac remodeling, most often in the form of hy-
pertrophy and associated myocardial ﬁbrosis (22,23).
Initially, the LV ejection fraction (EF) tends to in-
crease and, as such, supranormal values of LVEF
(>60%) are common. However, if untreated, pro-
gressive impairment of LV systolic function is indic-
ative of the afterload mismatch and, at some degree,
of the presence of myocardial ﬁbrosis, which may be
irreversible (23,24). In w25% of patients, LVEF does
not improve after AVR, which is associated with
adverse long-term outcomes (25,26). Currently,
LVEF <50% is considered the appropriate threshold
for deﬁning LV systolic dysfunction and referring
asymptomatic AS patients to AVR (9,10). In theHAVEC registry, patients with EF between 50% and
59% had less favorable outcomes and experienced
more heart failure–related deaths than those with EF
>60% (4-year survival: 68  4% vs. 87  2% in those
with EF <60% vs. $60%, respectively; p < 0.05), even
after AVR (20). These data reinforce observations
from previous retrospective studies (27,28) and pro-
vide support for a threshold of LVEF <60% instead
of <50% to deﬁne dysfunction.
Although the ﬁnding of excessive LV hypertrophy
in the absence of hypertension was removed from
guidelines for AVR indication (9,10), inappropriate
high LV mass (>110% of that expected for body size,
sex, and wall stress) heralds a signiﬁcant increased
risk of mortality independent of other known risk
factors (29).
Reduced LV GLS is an early marker of impaired
contractile function when EF is still preserved and is
also associated with the presence of myocardial
ﬁbrosis (30–32). Emerging data indicate that GLS may
have important prognostic potential in patients with
preserved EF, although the majority of patients
studied to date have been symptomatic, including
those undergoing AVR (16,33,34). Small series in
asymptomatic patient have also linked GLS with
subsequent cardiac events (18,35) and worsening of
strain abnormalities as AS progresses despite the lack
of a simultaneous fall in EF (36). The risk of death for
patients with an absolute GLS <14.7% has been shown
to be 2.5-fold higher in a recent individual participant
data meta-analysis (37). Although the precise role and
threshold used for clinical decision-making require
further study, evidence is accumulating for the
prognostic signiﬁcance of impaired GLS in patients
with signiﬁcant AS and preserved EF.
LEFT ATRIAL SIZE AND PULMONARY HYPERTENSION.
Left atrial size increases with worsening diastolic
dysfunction, reﬂects the magnitude and the chro-
nicity of increased LV ﬁlling pressure, and is associ-
ated with cardiac events in patients with AS (18).
Although conventional diastolic parameters (E/A,
E/e0) are not related to symptomatic deterioration,
reduced mitral annulus systolic and late diastolic
velocity (s0 <4.5 cm/s, a0 <9 cm/s) are associated
with cardiac events, including AVR (38). Pulmonary
hypertension is a sign of advanced disease stage
and is a robust prognostic parameter in AS (39–41).
European guidelines recommend consideration for
AVR (Class IIa) in patients with pulmonary artery
systolic pressure >60 mm Hg at rest conﬁrmed by
invasive measurement (without other explanation)
and if the risk of intervention is low (10).
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Echocardiography in an asymptomatic patient with severe aortic valve calciﬁcation (two- and three-dimensional short-axis views), very severe aortic stenosis (AS) (peak
velocity >5 m/s), preserved left ventricular ejection fraction (LVEF) (but LVEF <60%), reduced global longitudinal strain (GLS) (<14.7%), pulmonary hypertension
(systolic pulmonary hypertension [SPAP] >60 mm Hg), and impaired left atrial function (a0: peak late diastolic velocity by tissue <9 cm/s). All these parameters are
associated with poor outcomes.
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5EXERCISE TESTING. Exercise testing is contra-
indicated in patients with severe AS and symptoms
related to the valve disease. In contrast, exercise
testing should be considered in asymptomatic pa-
tients with severe AS after a careful history (9,10) as
this method may unmask symptoms or abnormal
blood pressure responses (42–44). However, there are
challenges in interpreting exercise test results,
particularly in patients with baseline electrocardio-
gram abnormalities (6). Up to 20% of patients with AS
are unable to perform a stress test due to poor
mobility, and impaired exercise capacity and exer-
tional dyspnea may be related to physical decondi-
tioning independent of AS severity. Although a
negative exercise test result is a reassuring ﬁnding in
younger patients, the predictive value of the test islower in older adults and may be further improved
when combined with echocardiographic assessment
of LV function, transvalvular pressure gradients, and
pulmonary arterial pressure (39,43–47). However,
current guidelines do not recommend exercise echo-
cardiography in asymptomatic patients with AS, and
its role in patient management requires further
investigation.
THE CASE FOR STAGING OF AS SEVERITY
Stratiﬁcation and recommendations for AVR in pa-
tients presenting with AS rely mainly on 2 criteria: 1)
the demonstration of severe stenosis based on
valvular criteria, including Vmax, mean gradient, and
aortic valve area (AVA) or aortic valve area index; and
FIGURE 2 Risk Stratiﬁcation of Aortic Stenosis Based on the Extent of Cardiac Damage
No Cardiac Damage
Echocardiogram
Stage 0 Stage 1

















Increase LV Mass Index
>115 g/m2 Male
>95 g/m2 Female
Stage 2 Stage 3 Stage 4
Stages/Criteria
Reproduced with permission of European Society of Cardiology from Genereux et al. (48). LV ¼ left ventricular; RV ¼ right ventricular.
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62) the presence or absence of symptoms related to AS
(9,10). In addition, risk stratiﬁcation of patients being
considered for AVR is currently based on surgical risk
scores (e.g., the Society of Thoracic Surgeons [STS]
Predicted Risk of Mortality Score) and the presence of
additional comorbidities (e.g., frailty, chronic
obstructive pulmonary disease, renal failure). The
current AVR decision algorithm does not take into
consideration the importance of anatomical or func-
tional cardiac consequences of AS with the exception
of reduced LV systolic function, deﬁned as an
LVEF <50%.
NOVEL STAGING CLASSIFICATION BASED ON THE
EXTENT OF CARDIAC DAMAGE. Recently, a novel
anatomic and functional cardiac staging classiﬁcation
was described for patients with severe AS undergoing
AVR that was based on the extent of extravalvular
cardiac “damage” (48). In this study, 1,661 patients
with severe AS undergoing TAVR or SAVR in the
PARTNER 2 (Placement of Aortic Transcatheter Valves
2) trials were pooled and classiﬁed in different stages
according to the presence or absence of cardiac
damage as detected by pre-AVR: no extravalvular
cardiac damage (stage 0), LV damage (stage 1), left
atrial or mitral valve damage (stage 2), pulmonary
vasculature or tricuspid valve damage (stage 3), orright ventricular damage (stage 4) (Figure 2). At 1 year,
all-cause death and cardiac death signiﬁcantly
increased with each stage of worsening cardiac dam-
age. Furthermore, after multivariable analysis and
when tested in multiple models, stage of cardiac
damage was shown to be signiﬁcantly associated with
1-year death, with an adjusted mortality hazard ratio
of w1.45 with each increase in stage, even after
adjusting for frailty and STS score. This new multi-
parametric staging classiﬁcation objectively charac-
terized the extent of anatomical and functional
cardiac damage associated with AS before AVR and
illustrated the important prognostic implications af-
ter AVR.
Admittedly, this staging system was derived in
symptomatic patients at intermediate surgical risk
(48). The components of each stage are not speciﬁc
for AS alone, and higher stages could reﬂect the effect
of cumulative cardiac and noncardiac comorbid fac-
tors that contribute to poor outcomes after AVR,
including concomitant coronary artery disease (CAD),
hypertension, atrial ﬁbrillation, and chronic lung
disease. Further studies are needed to prospectively
validate this classiﬁcation across different AS sever-
ities (i.e., mild, moderate, and severe) and to deﬁne
whether it could be integrated with the existing
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7algorithms in guiding the timing of AVR for asymp-
tomatic patients with AS.
THE CASE FOR BLOOD BIOMARKERS
Blood biomarkers offer the promise of a simple,
accessible way to gather additional information
that might reﬁne or clarify patient risk and optimize
recommendations regarding the timing of AVR.
Although all patients with severe AS might not beneﬁt
from AVR before symptoms occur, circulating bio-
markers could conceivably identify a subgroup of
patients who may beneﬁt from earlier AVR.
Biomarkers may reﬁne assessment of the relative
adaptive versus maladaptive nature of the hypertro-
phic remodeling that occurs in response to progres-
sive valve obstruction and pressure overload
(Figure 3). Several studies have now documented that
increased LV hypertrophic remodeling is associated
with worse systolic function, worse heart failure
symptoms, and increased mortality, but cardiac
hypertrophy in response to pressure overload is not
simply all good or all bad; both adaptive and mal-
adaptive processes are involved (49–54). LV mass and
geometry are only part of the story; the composition
and energetics of the myocardium are also important
(54). For example, it is now clear that cardiac ﬁbrosis
is associated with impaired symptomatic improve-
ment and increased mortality after AVR, but the
amount of ﬁbrosis is not strongly related to the
degree of hypertrophic remodeling (30). Accordingly,
simplistic cut-points to trigger surgical referral based
on the LV mass or geometry will likely be too insen-
sitive and nonspeciﬁc.
The ability to characterize the myocardial tissue in
patients with LV hypertrophy could be helpful as a
complement to measures of mass and geometry, of-
fering more insight into the health of the hypertro-
phic remodeling response. Results of myocardial
biopsy could provide this information, but it is an
expensive, invasive procedure with sampling bias.
CMR can detect myocardial ﬁbrosis via late gadolin-
ium enhancement (LGE) or measurement of extra-
cellular volume with T1 mapping, but these methods
are expensive and not widely available. Circulating
biomarkers offer a simple, accessible alternative,
albeit more indirect, to gain insight into the health of
the hypertrophic remodeling response in patients
with AS. For example, preclinical studies have
shown the role that markers such as sST2, GDF15, and
high-sensitivity troponin play in the biology of
hypertrophic remodeling, and studies in non-AS and
AS populations have reported their association with
prognosis (22,55–61).To date, most biomarker studies involving patients
with valvular heart disease in general and AS in
particular have focused on the natriuretic peptides
(62–65). Collectively, these studies show an associa-
tion between natriuretic peptide levels and symptom/
event-free survival and post-operative symptoms, LV
function, and mortality. However, the biology of the
hypertrophic remodeling response to pressure over-
load is more complex than altered myocardial stretch
and strain. More recent studies have evaluated the
association between other biomarkers, including
multiple biomarkers in combination, and outcomes in
patients with AS (60,61,65–68).
Despite these studies, the AHA/ACC and
ESC/EACTS guidelines do not offer a clear role for
biomarkers in the management of patients with AS
(9,10). The AHA/ACC guidelines make no mention of
biomarkers, whereas the ESC/EACTS guidelines
currently indicate that valve replacement is reason-
able (Class IIa) in an asymptomatic patient with a
“markedly elevated natriuretic peptide level” deﬁned
as levels 3-fold greater than the age- and sex-
corrected normal range, conﬁrmed by repeated
measurements without other explanations (10).
Further investigation is needed to show an adverse
association between increased levels of certain bio-
markers and clinical outcomes before they can be
incorporated into the clinical management of patients
with asymptomatic AS. Although data suggest the
possibility that asymptomatic patients with elevated
natriuretic peptide levels or other biomarkers of
cardiovascular stress may beneﬁt from earlier AVR
(60–62,64,65,68), this theory has not been tested. The
same could be said about other threshold values
included in the guidelines (e.g., EF, peak aortic jet
velocity, mean gradient), but these are well imbedded
in clinical decision-making. Adding or comparing a
biomarker risk score to existing clinical risk scores
should not be the goal, although it may be an inter-
mediate step in providing proof of concept data.
Rather, the most likely utility for biomarkers in
optimizing the timing of SAVR or TAVR is to identify
patients with progressively maladaptive hypertrophic
remodeling and subclinical dysfunction that place
them at risk for LV impairment and heart failure after
AVR if intervention is delayed until development of
symptoms or overt evidence of LV systolic function.
Simple dichotomous biomarker cut-points are
unlikely to be helpful, as biomarker levels will require
accounting for age, sex, race/ethnicity, body size,
renal function, and other factors (68). Furthermore,
given the complexity of the biology, and as studies in
non-AS populations have shown, it is likely that
multiple biomarkers will have greater utility than a












The transition from hypertrophy to heart failure is driven by both progressive myocyte cell death and by myocardial ﬁbrosis. LV ¼ left
ventricular.
Lindman et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . - , N O . - , 2 0 1 9
Asymptomatic Aortic Stenosis - 2 0 1 9 :- –-
8single biomarker in identifying patients who may
beneﬁt from earlier AVR (69). Change versus stability
of longitudinal measurements of biomarkers may be
more informative than isolated assessments.
The EARLY TAVR Trial will include a biobank,
which should facilitate greater understanding of the
role of biomarkers in risk stratiﬁcation of asymp-
tomatic patients with severe AS. Similarly, high-
sensitivity troponin I (hsTnI) is being used in the
EVOLVED trial (described in a later section) as a
method for selecting high-risk asymptomatic patients
most likely to beneﬁt from early AVR.
THE RATIONALE FOR THE EARLY TAVR TRIAL
Although current guidelines recommend AVR for
selected patients with asymptomatic severe AS (9,10),
in practice, an active surveillance strategy is adopted
for the majority of asymptomatic patients, with
intervention considered only when symptoms
emerge or LV systolic dysfunction develops. This
strategy has some well-appreciated practical chal-
lenges. It is often challenging for patients and
clinicians to interpret symptoms or the lack thereof,
particularly in sedentary elderly patients. Delayed
reporting of symptoms can result in irreversible
myocardial damage with suboptimal outcome after
AVR. Given that AS progression is highly variable
and unpredictable, rapid deterioration may occur.
Operative risk increases with patient age and LV
dysfunction. The risk of sudden death in patients
with severe AS without classic symptoms has been
estimated between 1% and 3% per year, depending
on the patient population studied (15,70). Finally, awell-deﬁned and validated algorithm for active sur-
veillance is lacking.
Given the low periprocedural mortality and
morbidity rates for isolated AVR in contemporary
practice, especially for TAVR, earlier intervention has
been increasingly advocated. However, early referral
to AVR has never been tested against a conservative
strategy of surveillance in patients with asymptom-
atic severe AS in a randomized trial. The lack of
robust data to support guideline recommendations
for asymptomatic patients, paired with the emer-
gence of TAVR as a viable and less invasive alterna-
tive to SAVR, has led to the conception of the EARLY
TAVR trial as cited earlier. This trial is a prospective,
randomized controlled, multicenter study, enrolling a
total of 1,109 patients. Patients included in this
trial must be $65 years of age, asymptomatic, and
diagnosed with severe AS (deﬁned as AVA #1.0 cm2 or
AVA index #0.6 cm2/m2 and Vmax $4.0 m/s or mean
gradient $40 mm Hg). Major exclusion criteria
include: STS scores >10%; LVEF <50%; any concom-
itant valvular, aortic, or CAD requiring surgery; and
unsuitability for transfemoral TAVR. Before enroll-
ment, most patients will undergo a low-level tread-
mill stress test to conﬁrm their asymptomatic status.
Patients who cannot safely perform a treadmill stress
test (i.e., those with orthopedic issues, frailty, or
limited mobility) may also be considered for enroll-
ment in the trial, pending review by a dedicated
executive committee. The primary endpoint at 2
years is a composite of all-cause death, all stroke, and
unplanned cardiovascular hospitalization, powered
for superiority. To complement the EARLY TAVR
trial, the pre-deﬁned biomarker substudy (with blood
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Areas of replacement ﬁbrosis can be detected using magnetic resonance imaging and the late gadolinium enhancement (LGE) technique in a midwall distribution (red
arrows) in patients with aortic stenosis (A). Midwall LGE is associated with an adverse prognosis. Kaplan-Meier curves for all-cause mortality are shown from patient
cohorts in (B) London (78), (C) Brussels (77), and (D) Edinburgh (24) and illustrate the poor prognosis associated with midwall LGE compared with patients with no LGE.
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FIGURE 5 Summary of Protocol for the EVOLVED Trial
B: Routine care
Follow-up until 88 events accrued








Mid-wall LGE No mid-wall LGE
CMR
• History and medications / NYHA status
• WHODAS 2.0 / Edmonton Frail Scale
• Blood pressure / blood sample
Baseline assessment
• Elevated hs-Tnl
• ECG criteria for LVH / strain
Screening
C: Routine care D: No further study
follow-up
Asymptomatic patients with severe aortic stenosis are ﬁrst screened for left ventricular decompensation by using high-sensitivity troponin I
(hs-TnI) and electrocardiogram (ECG). A total of 1,000 patients at higher risk for left ventricular decompensation (e.g., troponin levels
>6.0 ng/l) then proceed to magnetic resonance imaging. Patients with midwall LGE are considered to have objective evidence of left ven-
tricular decompensation and are randomized 1:1 to undergo early surgical aortic valve replacement/transcatheter aortic valve replacement
versus routine care. Patients without ﬁbrosis are also randomized to receive treatment. This method will ensure that blinding is maintained
among patients undergoing routine care and follow-up who have an equal chance of having or not having midwall ﬁbrosis. CMR ¼ cardiac
magnetic resonance; LVH ¼ left ventricular hypertrophy; NYHA ¼ New York Heart Association; WHODAS 2.0 ¼ World Health Organization
Disability Assessment Schedule 2.0.
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10collected in both randomization arms, at baseline,
and pre- and post-TAVR) will provide meaningful
biological insight to evaluate the potential beneﬁt of a
biomarker-driven early intervention strategy. The
results of the EARLY TAVR trial have the potential to
substantially inﬂuence the future management para-
digms for patients with severe asymptomatic AS.
THE CASE FOR MIDWALL FIBROSIS
AND THE EVOLVED TRIAL
Histopathological studies have shown that the 2 key
processes driving LV decompensation and the tran-
sition from hypertrophy to heart failure are progres-
sive myocyte death and myocardial ﬁbrosis (71). Both
are therefore important potential biomarkers of LV
decompensation. They are believed to develop as a
consequence of supply–demand ischemia in a hy-
pertrophied left ventricle that has outgrown its blood
supply (72).
Levels of hsTnI now allow detection of low-level
myocyte cell death and injury due to a range of
different cardiovascular conditions beyondmyocardial infarction. In patients with AS, hsTnI
levels relate not to the burden of CAD but instead to
the magnitude of the hypertrophic response and the
presence or absence of myocardial ﬁbrosis (60).
Myocardial ﬁbrosis is also detectable with the use
of modern noninvasive imaging techniques. Indeed,
CMR can detect areas of replacement ﬁbrosis in pa-
tients with AS by using the widely applied LGE
technique (73). A midwall pattern of LGE is observed
that can be differentiated from scarring due to other
causes (e.g., myocardial infarction, cardiac amyloid-
osis) and that is associated with multiple other
markers of LV decompensation such as advanced LV
hypertrophy, reductions in diastolic and systolic
function, increased symptomatic status, and reduced
exercise capacity (Figure 4) (23,24,30). Once it ﬁrst
develops, further midwall LGE accumulates rapidly in
the ventricle and is irreversible even after AVR (74).
As a consequence, the myocardial scarring that pa-
tients develop while waiting for AVR persists into the
long term, potentially governing myocardial health
and adverse events well beyond valve intervention.
Consistent with this hypothesis, midwall LGE has
HIGHLIGHTS
 Although AS is the most common heart
valve lesion encountered in clinical
practice, affecting 2% to 5% of older
adults, determining its severity in
asymptomatic patients remains
problematic.
 New methods of risk stratiﬁcation for
asymptomatic patients with AS are
emerging, including circulating bio-
markers, Doppler-derived global longi-
tudinal strain, and magnetic resonance
assessment of left ventricular myocardial
ﬁbrosis.
 Prospective randomized trials are under-
way for asymptomatic patients with AS to
assess timing of aortic valve replacement
and determinants of clinical outcomes.
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11been conﬁrmed as a powerful long-term prognostic
marker in several independent studies (23,24,75–78).
This occurs in a dose dependent manner, with the
more LGE, the higher the rates of adverse cardiovas-
cular events (23). A rationale is therefore evolving to
consider whether AVR should be performed when
midwall LGE is ﬁrst identiﬁed to prevent further
progression of ﬁbrosis and to improve long-term
clinical outcomes.
RATIONALE FOR THE EVOLVED TRIAL: TARGETING
EARLY AORTIC VALVE INTERVENTION TO PATIENTS
WITH OBJECTIVE EVIDENCE OF LV DECOMPENSATION.
The EVOLVED study is a multicenter, randomized
controlled trial investigating such a strategy and
whether objective markers of LV decompensation can
be used to optimize the timing of AVR (Figure 5).
Asymptomatic patients with severe AS will initially be
screened for LV decompensation by using hsTnI and
electrocardiography. Those patients with a normal
level (<6 ng/l) on this simple inexpensive blood
marker will be considered to have healthy myocar-
dium and continue to undergo routine clinical follow-
up. Patients with an elevated troponin level or an
electrocardiographic strain pattern (a marker of
myocardial ﬁbrosis) (79) will proceed to CMR to
conﬁrm whether they have LV decompensation due
to AS. Patients in whom midwall LGE is identiﬁed will
then be randomized to receive either early AVR
(TAVR or SAVR at the discretion of the clinical care
team) or the standard watchful waiting approach. The
primary endpoint is a composite of all-cause death or
unplanned AS-related hospital admission (unplanned
admission with syncope, heart failure, chest pain,
ventricular arrhythmia, or high-degree atrioventric-
ular block). The study is powered on the basis of 88
events across the patient population.
The aim of this novel approach is to identify both
the high-risk patients who will beneﬁt most from
early valve intervention and the asymptomatic pa-
tients with a healthy myocardium in whom major
heart intervention can be safely delayed. EVOLVED
will investigate whether this personalized medicine
approach can optimize the timing of AVR, improve
long-term patient outcomes, and therefore justify the
costs of this stratiﬁed biomarker/imaging approach.
CONCLUSIONS
As treatment options for managing symptomatic pa-
tients with AS expand at an astounding rate, fueled
by the TAVR revolution, the diagnostic armamen-
tarium with which to evaluate asymptomatic patients
with this condition has also continued to evolverapidly. Echocardiography will continue to be the
clinical workhorse for initial diagnosis and routine
re-evaluation. However, echocardiography is also
expanding its diagnostic horizons, principally
through advances in strain imaging. The coupling of
these newer echocardiographic modalities with
advanced CMR imaging of myocardial ﬁbrosis and the
use of multiple serum biomarkers hold promise for
the earlier identiﬁcation of patients with AS who can
be treated effectively before the onset of irreversible
structural and functional myocardial changes that
would otherwise impair long-term outcomes. Several
ongoing strategy trials are enrolling patients with
severe asymptomatic AS with or without additional
high-risk markers and randomizing them to receive
early intervention or clinical surveillance with
delayed AVR when symptoms occur. These trials are
anticipated to provide long-awaited, important evi-
dence to guide clinical decision-making on the timing
of valve replacement for the growing number of pa-
tients with asymptomatic AS.
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